Polymorphisms in HLA-G or KIR2DL4 could influence CD56bright NK cell function whose corresponding immunoregulatory pathway involves the already established MS susceptibility genes, the interleukin 2 receptor (IL2RA) and interleukin 7 receptor (IL7R) [2]. Here, KIR2DL4 is linked to myeloid sarcoma.